1. Home
  2. WTI vs FHTX Comparison

WTI vs FHTX Comparison

Compare WTI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo W&T Offshore Inc.

WTI

W&T Offshore Inc.

HOLD

Current Price

$2.40

Market Cap

309.5M

Sector

Energy

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.69

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTI
FHTX
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medicinal Chemicals and Botanical Products
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.5M
360.8M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
WTI
FHTX
Price
$2.40
$5.69
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$11.43
AVG Volume (30 Days)
2.3M
206.7K
Earning Date
03-02-2026
03-05-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$500,094,000.00
$24,518,000.00
Revenue This Year
N/A
$40.91
Revenue Next Year
$0.07
$11.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$2.95
52 Week High
$2.59
$6.95

Technical Indicators

Market Signals
Indicator
WTI
FHTX
Relative Strength Index (RSI) 61.72 47.69
Support Level $2.04 $5.18
Resistance Level $2.27 $5.79
Average True Range (ATR) 0.11 0.34
MACD 0.01 -0.10
Stochastic Oscillator 77.23 27.15

Price Performance

Historical Comparison
WTI
FHTX

About WTI W&T Offshore Inc.

W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: